Best Peptides for Longevity Research: 8 Anti-Aging Compounds
A ranked overview of eight compounds central to longevity and anti-aging research, spanning the telomere, mitochondrial, NAD+/sirtuin, and cellular-senescence theories of aging — from the investigational mitochondrial peptide SS-31 to the senolytic FOXO4-DRI.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Longevity research occupies one of the most conceptually crowded corners of the peptide literature. Where metabolic or tissue-repair research tends to organize around a single receptor or a defined injury model, aging research is defined by competing hypotheses about what drives biological decline: telomere attrition, mitochondrial dysfunction, cellular senescence, declining NAD+ availability, and the progressive dysregulation of gene-expression programs. The peptides and small molecules studied in this space are best understood not as a single class but as a set of probes, each one tied to a particular theory of aging and each one investigated against a different set of biomarkers — telomere length, sirtuin activity, mitochondrial membrane integrity, senescent-cell burden, or oxidative-stress markers.
This overview ranks eight compounds that recur most consistently in the published longevity and anti-aging literature. The ranking is built from the breadth and maturity of the peer-reviewed record, the diversity of documented mechanisms, the regulatory and clinical-development standing of each compound, and the directness of its link to a recognized hallmark of aging. It is not a recommendation, and it does not imply therapeutic equivalence between entries. Every compound below is described strictly in the context of laboratory or clinical research, with references drawn from PubMed-indexed studies summarized in the Clinical Peptide library.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
How we ranked
Compounds were scored on four dimensions. First, the volume and maturity of the published evidence base: compounds supported by both mechanistic and outcome studies — including any controlled human trials — rank above those defined only by isolated rodent or in vitro reports. Second, mechanism diversity: peptides whose effects have been documented across several independent pathways rank above those characterized by a single primary action. Third, regulatory and development standing: where a compound has advanced into formal clinical trials or carries a defined regulatory status, that is noted and weighted. Fourth, the directness of the link to an established hallmark of aging, as opposed to a more general or indirect mechanism.
Several caveats apply. Most of the compounds below are investigational or preclinical, and human longevity outcomes — by their nature slow to measure — have not been established for any of them. A high ranking reflects research prominence and mechanistic breadth, not safety, efficacy, or any approved anti-aging use. Where the human evidence is thin, that limitation is stated explicitly in each entry rather than smoothed over.
1. NAD+
NAD+ (nicotinamide adenine dinucleotide) sits at the center of one of the most heavily studied frameworks in aging biology: the decline of cellular NAD+ availability with age and its downstream effect on sirtuin-dependent signaling. Although NAD+ is a coenzyme rather than a peptide, it is cataloged here because it anchors the metabolic-aging hypothesis that several peptides in this list intersect with.
The mechanistic literature connects NAD+ to a network of regulatory pathways. A 2019 review, PMID 42044228, "Nature's Blueprint for Ischemic Tolerance: Preconditioning and Postconditioning Strategies," describes how a delayed adaptive window integrates NAD+/sirtuin pathways — including the PKCε→NAMPT→NAD+ axis and SIRT1 and SIRT5 control of glycolysis and mitochondrial desuccinylation — alongside metabolic reprogramming that reduces mitochondrial reactive oxygen species. These same pathways recur across the broader aging literature, where researchers study NAD+ precursors as a means of restoring sirtuin activity and mitochondrial efficiency in aged tissue.
NAD+ is not an approved anti-aging therapy and remains preclinical in this context, with compounding-eligibility review noted in its profile. The breadth of mechanistic literature, rather than any outcome data, is what places it first. See the NAD+ profile for full detail.
2. Epitalon
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide and the most direct representative of the telomere-maintenance hypothesis of aging among the compounds listed. It emerged from the Russian peptide-bioregulator research tradition and is studied principally for its reported effect on telomerase activity.
The mechanistic record is unusually specific for a longevity peptide. A 2025 study, PMID 41240216, "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity," reports dose-dependent telomere-length extension in normal human epithelial and fibroblast cells through upregulation of hTERT messenger RNA expression and telomerase enzyme activity, with a distinct alternative-lengthening-of-telomeres pathway observed in cancer cell lines. The authors frame telomere length as one biomarker of aging and position telomerase modulation as a candidate intervention point for healthy aging.
Epitalon is approved in Russia in a regulatory framework that differs substantially from FDA or EMA pathways; in most jurisdictions it remains a preclinical research compound, and its anti-aging claims rest largely on non-human and preliminary studies. Its high ranking reflects mechanistic directness rather than depth of controlled human data. See the epitalon profile.
3. SS-31
SS-31 (elamipretide) is the most clinically advanced compound on this list, having progressed into Phase 3 investigation, and it represents the mitochondrial-protection branch of aging research. It is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane through its affinity for cardiolipin, a phospholipid central to mitochondrial structure and function.
Research describes SS-31 primarily as a protector of mitochondrial integrity under oxidative stress. A 2026 study, PMID 42013545, "Peroxiredoxin III safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification," reports that the mitochondria-targeted antioxidant peptide SS-31 rescued mitochondrial dysfunction and cardiac injury driven by excessive hydrogen peroxide accumulation, protecting the inner membrane and preserving mitophagy and autophagic flux. Because mitochondrial dysfunction is one of the canonical hallmarks of aging, this mechanism links SS-31 directly to longevity-relevant biology.
SS-31 is classified as investigational and has been studied in formal clinical trials for mitochondrial and cardiac indications rather than for aging itself. It is not approved for any anti-aging use. Its ranking reflects its comparatively mature development stage among the entries. See the SS-31 profile.
4. MOTS-c
MOTS-c is a mitochondria-derived peptide — encoded within the mitochondrial genome rather than the nucleus — and it occupies the intersection of metabolic and mitochondrial aging research. It is studied as a regulator of metabolic homeostasis and as a candidate mediator of the metabolic benefits associated with exercise.
The published literature links MOTS-c to insulin sensitivity and metabolic regulation. A 2026 study, PMID 41945630, "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?", describes MOTS-c as a mitochondria-derived peptide associated with reduced insulin resistance and obesity, and examines how a specific genetic polymorphism relates to circulating peptide levels and metabolic parameters. In the longevity context, researchers study MOTS-c as part of the mitochondrial-derived-peptide family thought to communicate mitochondrial status to the rest of the cell — a signaling axis that declines with age.
MOTS-c is preclinical and not approved for any use; the available human data are largely observational associations rather than interventional outcomes. Its ranking reflects mechanistic interest in mitochondrial-nuclear signaling. See the MOTS-c profile.
5. Humanin
Humanin is the first-described member of the mitochondria-derived peptide family and a frequent companion to MOTS-c in aging research. It is studied principally as a cytoprotective and metabolic-signaling peptide, with particular attention to the aging brain.
A 2026 randomized controlled trial, PMID 41975304, "Preserving brain health in aging: structural and biochemical benefits of water-based resistance training," measured Humanin alongside FGF21, GDF-15, BDNF, and IGF-1 as mitochondrial-related growth factors in older adults, reporting that a 12-week training program increased these markers while reducing oxidative-stress and inflammatory indices and preserving brain structural integrity. The study illustrates how Humanin is used as a biomarker of mitochondrial and metabolic status in human aging research, even where the peptide itself is not the administered intervention.
Humanin is preclinical as a research compound and not approved for any use. Its inclusion reflects its foundational role in the mitochondrial-derived-peptide literature and its recurring use as an aging biomarker, rather than interventional outcome data. See the Humanin profile.
6. FOXO4-DRI
FOXO4-DRI (D-Retro-Inverso) represents the senolytic branch of longevity research — the strategy of selectively clearing senescent cells, which accumulate with age and secrete pro-inflammatory factors. It is a synthetic peptide engineered specifically to disrupt a protein-protein interaction rather than to engage a receptor.
The defining study, PMID 28340339, "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging," reports that FOXO4-DRI disrupts the FOXO4-p53 interaction that keeps senescent cells in a survival state; by releasing p53 to the cytoplasm, the peptide selectively triggers apoptosis in senescent cells while sparing healthy cells. In aged mice, the authors observed restored fur density, improved kidney function, and increased exercise tolerance — a set of outcomes that made the study a frequently cited proof of concept for senolytic strategies.
FOXO4-DRI remains a preclinical research compound; no human clinical trials have been conducted, and its effects are documented in animal models only. Its ranking reflects its mechanistic distinctiveness and citation prominence within senescence research. See the FOXO4-DRI profile.
7. GHK-Cu
GHK-Cu is a copper-bound tripeptide complex (glycyl-L-histidyl-L-lysine plus a copper ion) whose longevity relevance comes from its documented effects on gene expression and connective-tissue remodeling. Although it is most heavily studied in dermatology and wound healing, it appears in aging research because circulating GHK levels decline with age and because of its broad transcriptional footprint.
A 2026 review, PMID 41476424, "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians," surveys the evidence base for therapeutic peptides including copper tripeptides and emphasizes how limited the controlled human evidence remains relative to marketing claims. In the aging context, the GHK literature centers on the peptide's reported capacity to modulate a large number of genes associated with tissue remodeling, collagen synthesis, and antioxidant defense — a profile that connects it to the loss of regenerative capacity seen with age.
GHK-Cu is not an approved drug, though the underlying tripeptide is widely used as a cosmetic ingredient, and it carries compounding-review status. Its ranking reflects its gene-modulation breadth rather than direct longevity outcomes. See the GHK-Cu profile.
8. Pinealon
Pinealon (Glu-Asp-Arg) is a synthetic tripeptide from the Khavinson bioregulator family and represents the neuro-focused, gene-regulatory tradition of longevity research developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is studied primarily for neuroprotection in age-related cognitive-decline models.
A 2010 study, PMID 21161680, "Tripeptide Pinealon: neuroprotective and gene regulatory effects in aging brain," describes effects on neuronal gene expression, regulation of circadian-rhythm-associated pathways, and neuroprotection in age-related cognitive-decline models, with mechanistic work focusing on epigenetic modulation and direct peptide-DNA interaction in pineal and hypothalamic neurons. Pinealon is typically investigated alongside other Khavinson bioregulators, including Epitalon and Cortexin, as part of a shared hypothesis that short peptides can regulate tissue-specific gene-expression programs that drift with age.
Pinealon remains a preclinical research compound outside the Russian bioregulator framework, with an evidence base that is predominantly non-human and mechanistic. Its ranking reflects citation presence within a specific research lineage rather than breadth of independent validation. See the Pinealon profile.
Comparison table
| Compound | Primary mechanism (research) | Regulatory / development status | Reported half-life | Primary research application | Evidence volume |
|---|---|---|---|---|---|
| NAD+ | NAD+/sirtuin signaling, mitochondrial metabolic support | Not approved; preclinical (anti-aging) | Short; precursor-dependent | Metabolic-aging and sirtuin research | Extensive mechanistic |
| Epitalon | Telomerase (hTERT) upregulation, telomere extension | Russia approved; preclinical elsewhere | Short (tetrapeptide) | Telomere-maintenance research | Moderate (mostly non-human) |
| SS-31 | Cardiolipin binding, mitochondrial ROS reduction | Investigational; Phase 3 | Short (peptide) | Mitochondrial-protection research | Controlled human trials |
| MOTS-c | Mitochondria-derived metabolic signaling | Not approved; preclinical | Short (peptide) | Insulin-sensitivity and metabolic aging | Moderate; observational human |
| Humanin | Mitochondria-derived cytoprotective signaling | Not approved; preclinical | Short (peptide) | Mitochondrial and brain-aging biomarkers | Moderate; biomarker studies |
| FOXO4-DRI | FOXO4-p53 disruption, senescent-cell apoptosis | Not approved; preclinical | Short (engineered peptide) | Senolytic research | Limited; animal models |
| GHK-Cu | Copper-mediated gene modulation, tissue remodeling | Not a drug; compounding review | Short; copper-bound | Regenerative and gene-expression research | Moderate (dermatology) |
| Pinealon | Gene-expression and epigenetic modulation | Not approved; preclinical | Short (tripeptide) | Neuroprotection in aging models | Limited preclinical |
FAQ
Q: Why is NAD+ ranked first when it is a coenzyme rather than a peptide? A: The ranking reflects mechanistic centrality and the volume of published aging research, not chemical classification. NAD+ anchors the metabolic-aging and sirtuin framework that several of the listed peptides intersect with, which gives it the broadest mechanistic literature of the group. It is included as a research probe, not as an approved intervention.
Q: Which of these compounds is furthest along in clinical development? A: SS-31 (elamipretide) is the most advanced, having reached Phase 3 investigation for mitochondrial and cardiac indications. Its development status concerns those specific indications rather than longevity outcomes, and it is not approved for any anti-aging use. The remaining compounds are preclinical or investigational.
Q: What does the telomere hypothesis have to do with epitalon? A: Telomere shortening is one proposed hallmark of aging, and epitalon is studied specifically for its reported ability to upregulate telomerase, the enzyme that extends telomeres. The research record on this point is largely cell-line and non-human, so the mechanism is documented while human longevity outcomes remain unestablished.
Q: Are mitochondria-derived peptides such as MOTS-c and Humanin the same thing? A: They belong to the same family — peptides encoded within the mitochondrial genome that act as signaling molecules — but they are distinct compounds with different sequences and documented roles. Humanin was the first identified; MOTS-c is studied more for metabolic and exercise-related signaling. Both are cataloged as separate library entries.
Q: What is a senolytic, and how does FOXO4-DRI fit that category? A: A senolytic is a compound that selectively eliminates senescent cells, which accumulate with age and contribute to tissue dysfunction. FOXO4-DRI is an engineered peptide that disrupts the FOXO4-p53 interaction keeping senescent cells alive, triggering their apoptosis in preclinical models while sparing healthy cells.
Q: What does "preclinical" mean for the rankings on this page? A: Preclinical refers to research conducted in cell cultures (in vitro) or in animal models, before controlled human testing. Most compounds here are characterized only at this stage, which means their mechanisms are documented but their human efficacy, dosing, and safety for any aging-related application have not been established.
Cited studies
- PMID 42044228 — "Nature's Blueprint for Ischemic Tolerance: Preconditioning and Postconditioning Strategies." (2019). https://doi.org/10.1016/j.tins.2019.01.001
- PMID 41240216 — "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." (2025). https://doi.org/10.1023/A:1016027606368
- PMID 42013545 — "Peroxiredoxin III safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification." (2026). https://doi.org/10.1089/ars.2012.4849
- PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026). https://doi.org/10.1016/j.cmet.2015.01.013
- PMID 41975304 — "Preserving brain health in aging: structural and biochemical benefits of water-based resistance training, a randomized controlled trial." (2026). https://doi.org/10.1073/pnas.101208398
- PMID 28340339 — "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging." (2017). https://doi.org/10.1016/j.cell.2017.02.031
- PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." (2026). https://doi.org/10.1155/2015/648108
- PMID 21161680 — "Tripeptide Pinealon: neuroprotective and gene regulatory effects in aging brain." (2010). https://doi.org/10.1007/s10517-010-1066-1
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.